Stay updated with breaking news from Odile Smith. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Less than two years after the company’s site plan was approved, employees of Commonwealth Fusion Systems will soon begin moving into their new...
The hardest part for Odile Smith when she joined as vice president and Devens campus lead for Bristol Myers Squibb, a biopharma firm with $50 billion in annual revenue, wasn’t the work.
Central Massachusetts manufacturers must rise to meet demand and the challenges of the current crisis, using innovation and partners, according to a slate of experts at Worcester Business Journal's Central Mass Manufacturing Summit & Awards event Thursday at the College of the Holy Cross in Worcester.
Bristol Myers Squibb’s ongoing 244,000-square-foot expansion in Devens promises to define the former military reserve and further draw the state’s blossoming life sciences industry into Central Mass. In total, BMS’s campus sprawls 89 acres, with its cell therapy manufacturing addition slated to open in 2023.
Bristol Myers Squibb is growing. It’s in the process of expanding its Devens facility to handle new, cutting-edge manufacturing, including personalized cell therapy for patients with cancer.